litlas
Log inCreate account

Beow Y. Yeap

Active 1987–2026

117
Papers
23,344
Citations
85
h-index
112
i10-index

Citations

Citations per year for Beow Y. Yeap1976: 2 citations1985: 1 citations1988: 1 citations1989: 6 citations1990: 6 citations1991: 9 citations1992: 10 citations1993: 3 citations1994: 7 citations1995: 12 citations1996: 4 citations1997: 5 citations1998: 3 citations1999: 5 citations2000: 2 citations2001: 4 citations2002: 3 citations2003: 1 citations2004: 5 citations2005: 21 citations2006: 33 citations2007: 60 citations2008: 58 citations2009: 79 citations2010: 165 citations2011: 266 citations2012: 277 citations2013: 300 citations2014: 281 citations2015: 242 citations2016: 222 citations2017: 221 citations2018: 263 citations2019: 786 citations2020: 905 citations2021: 938 citations2022: 624 citations2023: 518 citations2024: 748 citations2025: 266 citations2026: 3 citations1977–1984: no citations, so these years are not shown1986–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,985 citing papers, 29.5% of this breakdownChina: 1,146 citing papers, 11.3% of this breakdownItaly: 629 citing papers, 6.2% of this breakdownGermany: 526 citing papers, 5.2% of this breakdownUnited Kingdom: 524 citing papers, 5.2% of this breakdownJapan: 512 citing papers, 5.1% of this breakdownFrance: 413 citing papers, 4.1% of this breakdownCanada: 308 citing papers, 3% of this breakdownSouth Korea: 287 citing papers, 2.8% of this breakdownSpain: 278 citing papers, 2.7% of this breakdownNetherlands: 269 citing papers, 2.7% of this breakdownAustralia: 228 citing papers, 2.3% of this breakdown
0%29.5%Other 19.9%

Institutions

Fields

  • Medicine79.9%
  • Biochemistry, Genetics and Molecular Biology14.9%
  • Immunology and Microbiology1.7%
  • Physics and Astronomy0.8%
  • Engineering0.7%
  • Computer Science0.5%
  • Other1.5%

Topics

  • Lung Cancer Treatments and Mutations13.2%
  • Lung Cancer Research Studies6.8%
  • Cancer Immunotherapy and Biomarkers4.9%
  • Lung Cancer Diagnosis and Treatment4.5%
  • Cancer Genomics and Diagnostics3.9%
  • Pancreatic and Hepatic Oncology Research2.5%
  • Other64.2%

Coauthors

All papers

Open in search
  1. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

    Authors: Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba R. Digumarthy, Teresa Morán, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino–Kenudson - Clinical Cancer Research 2016 cited by 1,241

  2. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial

    Authors: Aparna R. Parikh, Annamária Szabolcs, Jill N. Allen, Jeffrey W. Clark, Jennifer Y. Wo, Michael J. Raabe, Hannah L. Thel, David Hoyos, Arnav Mehta, Sanya Arshad, David Lieb, Lorraine C. Drapek, Lawrence S. Blaszkowsky, Bruce J. Giantonio, Colin D. Weekes, Andrew X. Zhu, Lipika Goyal, Ryan David Nipp, Jon S. Dubois, Emily E. Van Seventer, Bronwen Foreman, Lauren Matlack, Leilana Ly, Jessica Meurer, Nir Hacohen, David P. Ryan, Beow Y. Yeap, Ryan B. Corcoran, Benjamin D. Greenbaum, David T. Ting, Theodore S. Hong - Nature Cancer 2021 cited by 285

  3. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

    Authors: Janet E. Murphy, Jennifer Y. Wo, David P. Ryan, Jeffrey W. Clark, Wenqing Jiang, Beow Y. Yeap, Lorraine C. Drapek, Leilana Ly, Christian Baglini, Lawrence S. Blaszkowsky, Cristina R. Ferrone, Aparna R. Parikh, Colin D. Weekes, Ryan David Nipp, Eunice L. Kwak, Jill N. Allen, Ryan B. Corcoran, David T. Ting, Jason E. Faris, Andrew X. Zhu, Lipika Goyal, David L. Berger, Motaz Qadan, Keith D. Lillemoe, Nilesh P. Talele, Rakesh K. Jain, Thomas F. DeLaney, Dan G. Duda, Yves Boucher, Carlos Fernández-del Castillo, Theodore S. Hong - JAMA Oncology 2019 cited by 510

  4. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    Authors: Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson, Subba R. Digumarthy, Daniel B. Costa, Rebecca S. Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott, Jeffrey Settleman, Susumu Kobayashi, Eugene J. Mark, Scott J. Rodig, Lucian R. Chirieac, Eunice L. Kwak, Thomas J. Lynch, A. John Iafrate - Journal of Clinical Oncology 2009 cited by 1,882

  5. Therapy-induced APOBEC3A drives evolution of persistent cancer cells

    Authors: Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Faria M. Siddiqui, Nicole Phan, Pégah Jalili, Daria Timonina, Samantha Bilton, María Gomez‐Caraballo, Hannah L. Archibald, Varuna Nangia, Kristin Dionne, Amanda K. Riley, Matthew A. Lawlor, Mandeep K. Banwait, Rosemary Cobb, Lee Zou, Nicholas J. Dyson, Christopher J. Ott, Cyril H. Benes, Gad Getz, Chang S. Chan, Alice T. Shaw, Justin F. Gainor, Jessica J. Lin, Lecia V. Sequist, Zofia Piotrowska, Beow Y. Yeap, Jeffrey A. Engelman, Jake June-Koo Lee, Yosef E. Maruvka, Rémi Buisson, Michael S. Lawrence, Aaron N. Hata - Nature 2023 cited by 145

  6. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

    Authors: Anna F. Farago, Beow Y. Yeap, Marcello Stanzione, Yin P. Hung, Rebecca S. Heist, Judith Marcoux, Jun Zhong, Deepa Rangachari, David A. Barbie, Sarah Phat, David T. Myers, Robert Morris, Marina Kem, Taronish D. Dubash, Elizabeth A. Kennedy, Subba R. Digumarthy, Lecia V. Sequist, Aaron N. Hata, Shyamala Maheswaran, Daniel A. Haber, Michael S. Lawrence, Alice T. Shaw, Mari Mino–Kenudson, Nicholas J. Dyson, Benjamin J. Drapkin - Cancer Discovery 2019 cited by 238

  7. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

    Authors: Jessica J. Lin, Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Ted W. Johnson, Ramin Sakhtemani, Ibiayi Dagogo‐Jack, Subba R. Digumarthy, Charlotte Lee, Andrew Do, Jennifer Peterson, Kylie Prutisto-Chang, Wafa Malik, Harper Hubbeling, Adam Langenbucher, Adam J. Schoenfeld, Christina J. Falcon, Jennifer S. Temel, Lecia V. Sequist, Beow Y. Yeap, Jochen K. Lennerz, Alice T. Shaw, Michael S. Lawrence, Sai‐Hong Ignatius Ou, Aaron N. Hata, Alexander Drilon, Justin F. Gainor - Clinical Cancer Research 2021 cited by 139

  8. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer

    Authors: Justin F. Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo‐Jack, Luc Friboulet, W. Marston Linehan, Harper Hubbeling, Leila Dardaei, Anna F. Farago, Katherine R. Schultz, Lorin A. Ferris, Zofia Piotrowska, James C.H. Hardwick, Donghui Huang, Mari Mino–Kenudson, A. John Iafrate, Aaron N. Hata, Beow Y. Yeap, Alice T. Shaw - JCO Precision Oncology 2017 cited by 261

  9. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

    Authors: Ibiayi Dagogo‐Jack, Satoshi Yoda, Jochen K. Lennerz, Adam Langenbucher, Jessica J. Lin, Marguerite Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A. Adams, Beow Y. Yeap, Emily Chin, Andrew Do, Hetal D. Marble, Sara E. Stevens, Subba R. Digumarthy, Ashish Saxena, Rebecca J. Nagy, Cyril H. Benes, Christopher G. Azzoli, Michael S. Lawrence, Justin F. Gainor, Alice T. Shaw, Aaron N. Hata - Clinical Cancer Research 2020 cited by 194

  10. Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Authors: Alexa B. Turke, Kreshnik Zejnullahu, Yi‐Long Wu, Youngchul Song, Dora Dias‐Santagata, Eugene Lifshits, Luca Toschi, Andrew M. Rogers, Tony Mok, Lecia V. Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne - Cancer Cell 2010 cited by 1,062

  11. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

    Authors: Justin F. Gainor, Anna M. Varghese, Sai‐Hong Ignatius Ou, Sheheryar Kabraji, Mark M. Awad, Ryohei Katayama, Amanda C. Pawlak, Mari Mino–Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrate, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias‐Santagata, Alice T. Shaw - Clinical Cancer Research 2013 cited by 608

  12. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma

    Authors: Janet E. Murphy, Jennifer Y. Wo, David P. Ryan, Wenqing Jiang, Beow Y. Yeap, Lorraine C. Drapek, Lawrence S. Blaszkowsky, Eunice L. Kwak, Jill N. Allen, Jeffrey W. Clark, Jason E. Faris, Andrew X. Zhu, Lipika Goyal, Keith D. Lillemoe, Thomas F. DeLaney, Carlos Fernández‐del Castillo, Cristina R. Ferrone, Theodore S. Hong - JAMA Oncology 2018 cited by 543

  13. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

    Authors: Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott Antonia, Sarah Sagorsky, Marianne Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm, Lawrence H. Schwartz, Boris Sepesi, Beow Y. Yeap, Naiyer A. Rizvi, Roy S. Herbst - Journal for ImmunoTherapy of Cancer 2018 cited by 252

  14. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer

    Authors: W. Marston Linehan, Emily Chin, Beow Y. Yeap, Lorin A. Ferris, Vashine Kamesan, Inga T. Lennes, Lecia V. Sequist, Rebecca S. Heist, Mari Mino–Kenudson, Justin F. Gainor, Alice T. Shaw - Journal of Thoracic Oncology 2018 cited by 145

  15. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

    Authors: Aya Shiba‐Ishii, Ted W. Johnson, Ibiayi Dagogo‐Jack, Mari Mino–Kenudson, Theodore R. Johnson, Ping Wei, Scott L. Weinrich, Michele McTigue, Makeba Walcott, Linh Nguyen-Phuong, Kristin Dionne, Adam Acker, Lesli A. Kiedrowski, Andrew Do, Jennifer Peterson, Jaimie L. Barth, Beow Y. Yeap, Justin F. Gainor, Jessica J. Lin, Satoshi Yoda, Aaron N. Hata - Nature Cancer 2022 cited by 69

  16. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

    Authors: George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjørn Straume, Lars A. Akslen, Eugene Lifshits, Lauren A. Byers, Li Xu, Hua-Kang Wu, Pasi A. Jänne, Susumu Kobayashi, Balázs Halmos, Daniel G. Tenen, Xiaoou Tang, Jeffrey A. Engelman, Beow Y. Yeap, Judah Folkman, Bruce E. Johnson, John V. Heymach - Clinical Cancer Research 2009 cited by 348

  17. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

    Authors: W. Marston Linehan, Viola W. Zhu, Satoshi Yoda, Beow Y. Yeap, Alexa B. Schrock, Ibiayi Dagogo‐Jack, Nicholas A. Jessop, Ginger Jiang, Long P. Le, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, Vincent A. Miller, Melissa L. Johnson, Christine M. Lovly, Aaron N. Hata, Justin F. Gainor, A. John Iafrate, Alice T. Shaw, Sai‐Hong Ignatius Ou - Journal of Clinical Oncology 2018 cited by 337

  18. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

    Authors: Theodore S. Hong, Jennifer Y. Wo, Beow Y. Yeap, Edgar Ben‐Josef, Erin McDonnell, Lawrence S. Blaszkowsky, Eunice L. Kwak, Jill N. Allen, Jeffrey W. Clark, Lipika Goyal, Janet E. Murphy, Milind Javle, John A. Wolfgang, Lorraine C. Drapek, Ronald S. Arellano, Harvey J. Mamon, John T. Mullen, Sam S. Yoon, Kenneth K. Tanabe, Cristina R. Ferrone, David P. Ryan, Thomas F. DeLaney, Christopher H. Crane, Andrew X. Zhu - Journal of Clinical Oncology 2015 cited by 470

  19. Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

    Authors: Ibiayi Dagogo‐Jack, Marguerite Rooney, Jessica J. Lin, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw - Clinical Cancer Research 2019 cited by 150

  20. Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

    Authors: Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y. Yeap, Lynette M. Sholl, Bruce E. Johnson, Pasi A. Jänne - Clinical Cancer Research 2013 cited by 371

  21. Tumor Islands in Resected Early-stage Lung Adenocarcinomas are Associated With Unique Clinicopathologic and Molecular Characteristics and Worse Prognosis

    Authors: Maristela L. Onozato, Alexandra E. Kovach, Beow Y. Yeap, Vicente Morales‐Oyarvide, Veronica Klepeis, Swathi Tammireddy, Rebecca S. Heist, Eugene J. Mark, Dora Dias‐Santagata, A. John Iafrate, Yukako Yagi, Mari Mino–Kenudson - The American Journal of Surgical Pathology 2012 cited by 174

  22. Proton therapy for low‐grade gliomas: Results from a prospective trial

    Authors: Helen A. Shih, Janet C. Sherman, Lisa B. Nachtigall, Mary K. Colvin, Barbara C. Fullerton, Juliane Daartz, Barbara Winrich, Tracy T. Batchelor, Lauren T. Thornton, Sarah Mancuso, Michele K. Saums, Kevin Oh, William T. Curry, Jay S. Loeffler, Beow Y. Yeap - Cancer 2015 cited by 151

  23. Asymptomatic Late-phase Radiographic Changes Among Chest-Wall Patients Are Associated With a Proton RBE Exceeding 1.1

    Authors: Tracy Underwood, Clemens Grassberger, Rhedise Bass, Shannon M. MacDonald, Nandini M. Meyersohn, Beow Y. Yeap, Rachel Jimenez, Harald Paganetti - International Journal of Radiation Oncology*Biology*Physics 2018 cited by 122

  24. Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma

    Authors: Shervin Tabrizi, Beow Y. Yeap, Janet C. Sherman, Lisa B. Nachtigall, Mary K. Colvin, Michael Dworkin, Barbara C. Fullerton, Juliane Daartz, Trevor J. Royce, Kevin Oh, Tracy T. Batchelor, William T. Curry, Jay S. Loeffler, Helen A. Shih - Radiotherapy and Oncology 2019 cited by 89